ReviewCureus2025
Outcomes Following Stem Cell-Based Therapies for Hip Osteoarthritis: A Scoping Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hip osteoarthritis (OA) is a prevalent and debilitating condition for which current treatment options remain limited, especially in early to moderate stages. Stem cell-based therapies, particularly those using mesenchymal stem cells (MSCs), have gained attention due to their potential regenerative and anti-inflammatory properties. This scoping review aimed to map and summarize current clinical evidence on the efficacy and safety of intra-articular stem cell therapies for hip OA. This review followed the PRISMA-ScR guidelines and was registered on the Open Science Framework (DOI: 10.17605/OSF.IO/G8V9S). A systematic search of PubMed, Embase, Cochrane Library, Web of Science, and Scopus was conducted from December 2024 to January 2025. Inclusion criteria comprised clinical studies evaluating intra-articular stem cell-based therapies in adults with hip OA. Excluded were non-clinical studies, reviews, and studies involving joints other than the hip or non-stem cell interventions. Two reviewers independently selected studies and extracted data, resolving disagreements through discussion with a third reviewer. Out of 286 records identified, 9 studies met the inclusion criteria. These included five cohort studies and four case series, assessing various MSC sources: bone marrow-derived MSCs (BM-MSCs), adipose-derived MSCs (AD-MSCs), stromal vascular fraction (SVF), and amniotic-derived preparations. Pain reduction was consistently observed, with average visual analog scale (VAS) score reductions of 30-50%. Functional improvement was reported via metrics like the Harris Hip Score and Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC). Radiologic evidence of cartilage repair was limited and inconsistent. Adverse events were rare and mild, including transient joint discomfort and local swelling, with no major complications reported. Stem cell-based therapies show promising short- to mid-term outcomes in pain relief and functional improvement for hip OA, with favorable safety profiles. However, heterogeneity in study designs and limited long-term structural outcomes highlight the need for standardized protocols and robust randomized trials to confirm regenerative efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.